Biotech RadarJobs updated

COMPANY

OrsoBio

orsobio.com ↗

Clinical Phase 2

Keywords: metabolic obesity diabetes mellitus metabolic dysfunction-associated steatohepatitis Type 2 Diabetes Hypertriglyceridemia Nonalcoholic Fatty Liver Disease Insulin Resistance TLC-1180 TLC-6740 TLC-2716 TLC-3595

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects source ↗
  2. Trial start 2: Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD source ↗
  3. Trial start 1: Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes source ↗
  4. Trial start Phase 2: A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance source ↗
  5. Trial start Phase 1: A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07300189A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy SubjectsPhase 1RecruitingOct 20, 2025Mar 1, 2028 (estimated)
NCT05822544Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes1Active, not recruitingApr 22, 20232026-09 (estimated)
NCT06564584Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD2Unknown status (ClinicalTrials.gov)Aug 12, 20242025-06 (estimated)
NCT05665751A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin ResistancePhase 2Unknown status (ClinicalTrials.gov)Mar 8, 20232024-09 (estimated)
NCT05483998A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy ParticipantsPhase 1CompletedSep 9, 2022Apr 13, 2023 (actual)
Feedback